NR 566
FINAL EXAM
(Week’s 5 - 8)
Advanced Pharmacology for the Care of the Family
Exam-Style Qs that mirror the actual Exam
Chamberlain
This Exam Features:
• NR 566 Final Exam – Advanced Pharmacology
featuring 100 high-yield exam-style questions with
verified answers and detailed rationales.
• Designed for advanced practice nursing students
preparing for pharmacology finals, boards, and clinical application
exams.
,Question 1:
A 58-year-old patient asks why long-term hormone therapy (HT) is not
usually the first choice for osteoporosis prevention. Which response is
BEST?
A. HT prevents bone loss permanently even after it is stopped
B. Bone mass rapidly decreases after stopping HT, so ongoing lifelong use
would increase harm risk
C. HT only works if started before the first missed menstrual cycle
D. HT prevents fractures only when combined with calcium
supplementation
Answer: B. Bone mass rapidly decreases after stopping HT, so ongoing
lifelong use would increase harm risk
Expert Explanation: HT decreases postmenopausal bone loss, but bone
mass rapidly declines after discontinuation, so maintaining benefit would
require lifelong therapy and greater risk of harm.
Question 2:
Which medication is listed as an effective alternative to HT for osteoporosis
prevention?
A. Raloxifene
B. Methimazole
C. Acyclovir
D. Rasagiline
Answer: A. Raloxifene
Expert Explanation: Raloxifene is specifically listed as an effective
alternative to HT for reducing postmenopausal bone loss and fracture risk.
Question 3:
A patient with an intact uterus is prescribed systemic estrogen for hot
flashes. Which additional therapy is MOST consistent with the study guide’s
stated goal for progestins in hormone therapy?
A. Add a progestin to counteract endometrial hyperplasia from unopposed
,estrogen
B. Add a progestin to improve libido and reduce fatigue
C. Add a progestin to reduce serum triglycerides
D. Add a progestin to eliminate the need for weight-bearing exercise
Answer: A. Add a progestin to counteract endometrial hyperplasia from
unopposed estrogen
Expert Explanation: Progestins are used during hormone therapy to
counteract endometrial hyperplasia caused by unopposed estrogen.
Question 4:
Which patient history is a CONTRAINDICATION to prescribing progestins
per the study guide?
A. Undiagnosed abnormal vaginal bleeding
B. Controlled hypothyroidism
C. Seasonal allergic rhinitis
D. Mild acne treated with benzoyl peroxide
Answer: A. Undiagnosed abnormal vaginal bleeding
Expert Explanation: The study guide lists undiagnosed abnormal vaginal
bleeding as a contraindication to progestins.
Question 5:
Which patient is LEAST appropriate for progestin therapy in the context of
menopause management?
A. Patient with a hysterectomy using estrogen therapy
B. Patient with endometriosis symptoms
C. Patient needing support of pregnancy due to corpus luteum deficiency
D. Patient at high risk for preterm birth
Answer: A. Patient with a hysterectomy using estrogen therapy
Expert Explanation: The study guide states progestins should not be
prescribed for women who have undergone hysterectomy.
Question 6:
A patient wants treatment primarily for vulvovaginal atrophy symptoms.
, Which option is MOST aligned with the guide’s “local estrogen options”?
A. Vaginal inserts, creams, or rings
B. IV estrogen infusion
C. IM estrogen injections for routine therapy
D. Oral estradiol combined with a progestin
Answer: A. Vaginal inserts, creams, or rings
Expert Explanation: Intravaginal estrogens (inserts, creams, rings) are
listed as local options used primarily for vulval and vaginal atrophy
associated with menopause.
Question 7:
Which statement about Femring is MOST accurate according to the guide?
A. It is used only for local vulvovaginal atrophy
B. It is used for systemic effects to control hot flashes and night sweats
C. It is contraindicated in all menopause patients
D. It is an oral estrogen formulation
Answer: B. It is used for systemic effects to control hot flashes and night
sweats
Expert Explanation: The guide notes that Femring is also used for systemic
effects to control hot flashes and night sweats.
Question 8:
Which advantage of transdermal estrogen compared with oral estrogen is
listed in the study guide?
A. Higher total estrogen dose is required to achieve symptom control
B. Greater fluctuation in serum estrogen levels
C. Lower risk for DVT, PE, and CVA
D. Increased nausea and vomiting
Answer: C. Lower risk for DVT, PE, and CVA
Expert Explanation: The guide lists a lower risk for DVT, PE, and CVA as
an advantage of transdermal formulations versus oral formulations.
FINAL EXAM
(Week’s 5 - 8)
Advanced Pharmacology for the Care of the Family
Exam-Style Qs that mirror the actual Exam
Chamberlain
This Exam Features:
• NR 566 Final Exam – Advanced Pharmacology
featuring 100 high-yield exam-style questions with
verified answers and detailed rationales.
• Designed for advanced practice nursing students
preparing for pharmacology finals, boards, and clinical application
exams.
,Question 1:
A 58-year-old patient asks why long-term hormone therapy (HT) is not
usually the first choice for osteoporosis prevention. Which response is
BEST?
A. HT prevents bone loss permanently even after it is stopped
B. Bone mass rapidly decreases after stopping HT, so ongoing lifelong use
would increase harm risk
C. HT only works if started before the first missed menstrual cycle
D. HT prevents fractures only when combined with calcium
supplementation
Answer: B. Bone mass rapidly decreases after stopping HT, so ongoing
lifelong use would increase harm risk
Expert Explanation: HT decreases postmenopausal bone loss, but bone
mass rapidly declines after discontinuation, so maintaining benefit would
require lifelong therapy and greater risk of harm.
Question 2:
Which medication is listed as an effective alternative to HT for osteoporosis
prevention?
A. Raloxifene
B. Methimazole
C. Acyclovir
D. Rasagiline
Answer: A. Raloxifene
Expert Explanation: Raloxifene is specifically listed as an effective
alternative to HT for reducing postmenopausal bone loss and fracture risk.
Question 3:
A patient with an intact uterus is prescribed systemic estrogen for hot
flashes. Which additional therapy is MOST consistent with the study guide’s
stated goal for progestins in hormone therapy?
A. Add a progestin to counteract endometrial hyperplasia from unopposed
,estrogen
B. Add a progestin to improve libido and reduce fatigue
C. Add a progestin to reduce serum triglycerides
D. Add a progestin to eliminate the need for weight-bearing exercise
Answer: A. Add a progestin to counteract endometrial hyperplasia from
unopposed estrogen
Expert Explanation: Progestins are used during hormone therapy to
counteract endometrial hyperplasia caused by unopposed estrogen.
Question 4:
Which patient history is a CONTRAINDICATION to prescribing progestins
per the study guide?
A. Undiagnosed abnormal vaginal bleeding
B. Controlled hypothyroidism
C. Seasonal allergic rhinitis
D. Mild acne treated with benzoyl peroxide
Answer: A. Undiagnosed abnormal vaginal bleeding
Expert Explanation: The study guide lists undiagnosed abnormal vaginal
bleeding as a contraindication to progestins.
Question 5:
Which patient is LEAST appropriate for progestin therapy in the context of
menopause management?
A. Patient with a hysterectomy using estrogen therapy
B. Patient with endometriosis symptoms
C. Patient needing support of pregnancy due to corpus luteum deficiency
D. Patient at high risk for preterm birth
Answer: A. Patient with a hysterectomy using estrogen therapy
Expert Explanation: The study guide states progestins should not be
prescribed for women who have undergone hysterectomy.
Question 6:
A patient wants treatment primarily for vulvovaginal atrophy symptoms.
, Which option is MOST aligned with the guide’s “local estrogen options”?
A. Vaginal inserts, creams, or rings
B. IV estrogen infusion
C. IM estrogen injections for routine therapy
D. Oral estradiol combined with a progestin
Answer: A. Vaginal inserts, creams, or rings
Expert Explanation: Intravaginal estrogens (inserts, creams, rings) are
listed as local options used primarily for vulval and vaginal atrophy
associated with menopause.
Question 7:
Which statement about Femring is MOST accurate according to the guide?
A. It is used only for local vulvovaginal atrophy
B. It is used for systemic effects to control hot flashes and night sweats
C. It is contraindicated in all menopause patients
D. It is an oral estrogen formulation
Answer: B. It is used for systemic effects to control hot flashes and night
sweats
Expert Explanation: The guide notes that Femring is also used for systemic
effects to control hot flashes and night sweats.
Question 8:
Which advantage of transdermal estrogen compared with oral estrogen is
listed in the study guide?
A. Higher total estrogen dose is required to achieve symptom control
B. Greater fluctuation in serum estrogen levels
C. Lower risk for DVT, PE, and CVA
D. Increased nausea and vomiting
Answer: C. Lower risk for DVT, PE, and CVA
Expert Explanation: The guide lists a lower risk for DVT, PE, and CVA as
an advantage of transdermal formulations versus oral formulations.
